Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Real World

Oral therapy convinces MS patients

    • Market & Medicine
    • Neurology
    • RX
    • Studies
  • 3 minute read

Changes in therapy are frequent. In addition to the substance, the application also plays a role, as comparisons of clinical trial results and real-world data show.

Recognize languageAfrikaansAlbanianAmharicArabicArmenianAzerbaijaniBasqueBengaliBirmanBosnianBulgarianCebuanoChichewaChinese tradChinese verDänischDeutschEnglischEsperantoEstnischFilipinoFinnischFranzösischFriesischGalizischGeorgischGriechischGujaratiHaitianischHausaHawaiischHebräischHindiHmongIgboIndonesischIrischIsländischItalienischJapanischJavanesischJiddischKannadaKasachischKatalanischKhmerKirgisischKoreanischKorsischKroatischKurdischLaoLateinishLettischLitauischLuxemburgischMalagasyMalayalamMalaysischMaltesischMaoriMarathiMazedonischMongolischNepalesischNiederländischNorwegischPaschtuPersischPolnischPortugiesischPunjabiRumänischRussischSamoanischSchottisch-GaelicSerbianSesothoShonaSindhiSinghaleseSlovakSlovenianSomaliSpanishSwahiliSundaneseTajikTamilTeluguThailandCzechTurkishUkrainianHungarianUrduUzbekVietnameseWelshRussianXhosaYorubaZulu
 
AfrikaansAlbanianAmharicArabicArmenianAzerbaijaniBasqueBengaliBurmeseBosnianBulgarianCebuanoChichewaChinese tradChinese verDänischDeutschEnglischEsperantoEstnischFilipinoFinnischFranzösischFriesischGalizischGeorgischGriechischGujaratiHaitianischHausaHawaiischHebräischHindiHmongIgboIndonesischIrischIsländischItalienischJapanischJavanesischJiddischKannadaKasachischKatalanischKhmerKirgisischKoreanischKorsischKroatischKurdischLaoLateinishLettischLitauischLuxemburgischMalagasyMalayalamMalaysischMaltesischMaoriMarathiMazedonischMongolischNepalesischNiederländischNorwegischPaschtuPersischPolnischPortugiesischPunjabiRumänischRussischSamoanischSchottisch-GaelicSerbianSesothoShonaSindhiSinghaleseSlovakSlovenianSomaliSpanishSwahiliSundaneseTajikTamilTeluguThailandCzechTurkishUkrainianHungarianUrduUzbekVietnameseWelshRussianXhosaYorubaZulu
 
 
 
 
 
 

 
 
 
The sound function is limited to 200 characters
 
 
 
Options: History: Feedback: Donate Close

Randomized controlled trials (RCTs) remain the gold standard for testing various clinical questions. But when it comes to clinical practice, real-world data collection is essential. Real-world evidence studies inform not only rare side effects, but also mediation efficacy, residual disease activity, and reasons to change therapy. The basis is a large, heterogeneous patient collective that corresponds to real-life conditions.

At a press conference held by Sanofi Genzyme in Cologne, Germany, Univ. Prof. Dr. med. Luisa Klotz, senior physician at the Department of Neurology at Münster University Hospital, explained just such Real World data against the background of the results of clinical studies on teriflunomide. Teriflunomide is an immunomodulator with anti-inflammatory properties that is administered orally once daily. As Prof. Klotz pointed out, it is precisely this oral application that is important for many patients. This was also shown by the analyses of Sacca and colleagues, who investigated reasons for a change in therapy in 3025 MS patients at 24 sites. In three years, about half switched to a different therapy, with application playing a role in addition to the active ingredient. “A change in therapy, for example, occurred more often with injection therapy than with oral application,” Prof. Klotz specified.

Clinical studies on teriflunomide

The pivotal TEMSO and TOWER studies demonstrated a significant reduction in disability progression compared to placebo. In a post-hoc analysis of pooled data from both studies, the placebo comparison also showed a significant 53% reduction in the annual relapse rate with residuals. In terms of preventing relapses, teriflunomide is comparable to dimethyl fumarate, which is also given orally. The long-term efficacy and safety of teriflunomide have been demonstrated by long-term data from the pivotal studies and the Phase II extension study, which showed a low annualized relapse rate and stable EDSS (“Expanded Disability Status Scale”) over 12 years.

And in practice?

A prospective, multicenter, industry-independent observational study tested how many patients achieved NEDA (“No Evidence of Disease Activity”) status under real-world conditions with teriflunomide or dimethyl fumarate. Included were 468 patients with relapsing-remitting MS at therapy initiation with teriflunomide or dimethyl fumarate. Over an observation period of twelve months, both drugs proved to be comparable. However, teriflunomide was significantly better tolerated: patients treated with dimethyl fumarate had side effects more often than those taking teriflunomide (26.5% vs. 12%). This finding is quite relevant in practice, especially since side effects are a frequent reason for changing therapy.

Another observational study (TAURUS-MS-I; n=1128) over two years also indicates good practicality of teriflunomide. About three-quarters of participants had been pretreated at baseline and had switched to teriflunomide because of injection fatigue or flu-like side effects. Under this therapy, relapse rates decreased significantly and FSS (“Fatique Severity Scale”) scores stabilized. Patient satisfaction increased. The side effect profile was consistent with the results of the clinical trials, with increased ALT, headache, diarrhea, nausea, and decreased hair density being the most common, most of which were reversible. The reason for the increased patient satisfaction could be the ease of oral use and good tolerability with sustained efficacy, the study leader said.

Prof. Klotz summarizes: “The current real-world data on MS therapy with teriflunomide confirm the positive efficacy and safety profile from the pivotal and long-term studies and give no indication of unexpected side effects”.

 

InFo NEUROLOGY & PSYCHIATRY 2019; 17(3).

Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • Change of therapy
  • Multiple sclerosis
  • Real World
Previous Article
  • Anxiety disorders

What is the role of epigenetics?

  • Congress Reports
  • Genetics
  • Psychiatry and psychotherapy
  • RX
View Post
Next Article
  • Home Treatment

Acute treatment at home for people with mental illnesses

  • Education
  • Prevention and health care
  • Psychiatry and psychotherapy
  • RX
View Post
You May Also Like
View Post
  • 15 min
  • Diabetes mellitus

Treatment of comorbidities in older people

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • RX
View Post
  • 12 min
  • Liver steatosis with metabolic dysfunction

New nomenclature for non-alcoholic fatty liver disease

    • CME continuing education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 4 min
  • Type 2 diabetes: PAD and diabetic foot syndrome

Prevention is better than cure – don’t miss the risk foot

    • Cardiology
    • Congress Reports
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • Prevention and health care
    • RX
View Post
  • 2 min
  • Prostate cancer

High-resolution ultrasound could diagnose prostate cancer faster

    • Congress Reports
    • Oncology
    • RX
    • Studies
    • Urology
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 8 min
  • Psychooncology

Communication as the key to therapy adherence

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • RX
View Post
  • 16 min
  • Blastic plasmacytoid dendritic cell neoplasia

Rare malignancy from a dermatological perspective

    • CME continuing education
    • Dermatology and venereology
    • Genetics
    • Hematology
    • Oncology
    • RX
View Post
  • 4 min
  • From symptom to diagnosis

Lung carcinoma – Pancoast tumor

    • Cases
    • Education
    • Oncology
    • Pneumology
    • Radiology
    • RX
    • Surgery
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Treatment of comorbidities in older people
  • 2
    New nomenclature for non-alcoholic fatty liver disease
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Communication as the key to therapy adherence
  • 5
    Patience, knowledge and persistence in therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.